II
BHVN

Inspire Investing’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Inspire Investing’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,632
Closed -$1.61M – 776
2022
Q3 		$1.61M Buy
10,632
+9,179
+632% +$1.36M 0.23% 98
2022
Q2 		$212K Sell
1,453
-524
-27% -$66.9K 0.03% 625
2022
Q1 		$234K Buy
+1,977
New +$247K 0.03% 737

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Inspire Investing's BHVN Position: Q4 2022 in Review

Inspire Investing sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 10,632 shares — an estimated $1.61M sold.

Inspire Investing first reported a position in BHVN in Q1 2022 and held it in 3 quarters. The position peaked at $1.61M in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Inspire Investing reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Inspire Investing sold 10,632 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.61M.
  • Inspire Investing first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022 and held it in 3 quarters.
  • Inspire Investing's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.61M in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Inspire Investing's 13F filing for Q4 2022, filed 26 Jan 2023.